<DOC>
	<DOCNO>NCT02016482</DOCNO>
	<brief_summary>This study conduct assess safety efficacy adalimumab subject nail psoriasis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Adalimumab Subjects With Chronic Plaque Psoriasis Nail Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must body surface area ( BSA ) ≥ 10 % target fingernail Modified Nail Psoriasis Severity Index ( mNAPSI ) ≥ 8 Week 0 , OR BSA ≥ 5 % , target fingernail mNAPSI ≥ 8 total mNAPSI score ≥ 20 Week 0 . Subject must Nail Psoriasis Physical Functioning Severity score &gt; 3 , OR Nail Psoriasis Pain Numeric Rating Scale ( NRS ) score &gt; 3 . Subjects must Physician 's Global Assessment ( PGA ) Fingernail Psoriasis PGA Skin Psoriasis least moderate . Subject must discontinue use systemic therapy treatment psoriasis , systemic therapy know improve psoriasis least 4 week prior Week 0 , ustekinumab must discontinue least 12 week prior Week 0 . Target fingernail must mNAPSI score ≥ 8 . Adult subject clinical diagnosis chronic plaque psoriasis ( disease duration least 6 month ) . Prior adalimumab therapy . Diagnosis active skin disease skin infection ( bacterial , fungal , viral ) may interfere evaluation skin fingernail psoriasis . Recent infection require treatment . Significant medical event condition may put patient risk participation , include recent history drug alcohol abuse . Female subject pregnant breastfeed consider become pregnant study . History cancer , except successfully treat skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Nail Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
</DOC>